HilleVax, Inc.HilleVax, Inc. • April 6th, 2022 • Biological products, (no disgnostic substances) • California
HilleVax, Inc. (the “Company”) is pleased to continue to offer you a position on the terms set forth in this amended and restated offer letter (this “Agreement”). This Agreement is entered into effective March 1, 2021 and amends and restates in its entirety the offer letter between the Company and you that was dated February 8, 2021.
LICENSE AGREEMENT BY AND BETWEEN TAKEDA VACCINES, INC. AND HILLEVAX, INC.License Agreement • April 6th, 2022 • HilleVax, Inc. • Biological products, (no disgnostic substances) • New York
This License Agreement (this “Agreement”) is made effective as of July 2, 2021 (the “Effective Date”) by and between Takeda Vaccines, Inc., a company incorporated under the laws of Delaware having its principal place of business at 75 Sidney Street, Cambridge, Massachusetts 02139, U.S.A. (“Takeda”), and HilleVax, Inc., a company incorporated under the laws of Delaware having its principal place of business at 601 Union Street, Suite 3200, Seattle, Washington, 98101, U.S.A. (“Licensee”). Licensee and Takeda are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
ContractHilleVax, Inc. • April 6th, 2022 • Biological products, (no disgnostic substances) • Delaware
THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM.
EMPLOYMENT AGREEMENT betweenEmployment Agreement • April 6th, 2022 • HilleVax, Inc. • Biological products, (no disgnostic substances)
The Company has the right to assign other duties and responsibilities to the Employee which are in accordance with the Employee’s education and skills.
HilleVax, Inc.HilleVax, Inc. • April 6th, 2022 • Biological products, (no disgnostic substances) • Washington
HilleVax, Inc. (the “Company”) is pleased to offer you a position on the terms set forth in this letter (this “Agreement”), effective as of February 8, 2021.
HILLEVAX, INC. NOTE PURCHASE AGREEMENT August 31, 2021Note Purchase Agreement • April 6th, 2022 • HilleVax, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS NOTE PURCHASE AGREEMENT (“Agreement”) is made as of August 31, 2021, by and among HilleVax, Inc., a Delaware corporation (the “Company”), and the lenders (each, a “Lender” and collectively, the “Lenders”) named on the Schedule of Lenders attached hereto (the “Schedule of Lenders”), and the Common Holders (as defined herein) (collectively, the “Parties”). Capitalized terms not otherwise defined in this Agreement shall have the meanings ascribed to them in Section 1 below.
AGREEMENT OF MERGERAgreement of Merger • April 6th, 2022 • HilleVax, Inc. • Biological products, (no disgnostic substances) • Delaware
AGREEMENT OF MERGER, dated as of February 8, 2021 (this “Agreement”), among HilleVax, Inc., a Delaware corporation (“HilleVax”), YamadaCo III, Inc., a Delaware corporation (“YamadaCo”) and North Bridge V, Inc., a Delaware corporation (“North Bridge”).
